RPG Life Sciences Limited , a leading integrated pharmaceutical company, has announced its financial results for the first quarter of fiscal year 2026 and made a key appointment to strengthen its API business.

Q1 FY26 Financial Highlights

The company reported a modest growth in revenue for the quarter ended June 30, 2025:

Despite the challenging environment, RPG Life Sciences maintained a healthy EBITDA margin of 24.1% and saw a slight improvement in its PAT margin.

Segment-wise Performance

• Domestic Formulations: This segment, contributing 69% to total sales, showed strong growth of 9.5% year-on-year, reaching ₹115.50 crores.
• International Formulations: Contributing 19% to total sales, this segment experienced a slight decline of 2.7%, with revenues of ₹32.50 crores.
• API Business: The API segment, accounting for 12% of total sales, saw a significant decline of 22.4% due to a fire incident in one of the manufacturing blocks, with revenues of ₹19.60 crores.

Strategic Appointment

In a move to bolster its API business, RPG Life Sciences has appointed Mr. Deepak Shukla as Chief Executive - API Business, effective July 28, 2025. Mr. Shukla brings with him approximately 25 years of experience in the pharmaceutical industry, having worked with renowned companies such as UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy's Laboratories.

Management Commentary

Mr. Ashok Nair, Managing Director of RPG Life Sciences Ltd., commented on the results, stating, "In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach."

He further added, "We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach."

Future Outlook

The company is actively exploring inorganic growth opportunities across both formulations and APIs to accelerate its growth trajectory. With a strong focus on new product development, market expansion, and operational efficiency, RPG Life Sciences aims to create lasting value for all stakeholders.

The Board of Directors has also approved a revision in the policy for Determination of Materiality of Events in accordance with amended SEBI regulations, underlining the company's commitment to transparency and corporate governance.

As RPG Life Sciences continues to navigate the dynamic pharmaceutical landscape, its strategic initiatives and focus on core business segments position it well for future growth and market expansion.

RPG Life Sciences Limited , an integrated pharmaceutical company, has announced its financial results for the first quarter of the fiscal year 2026, demonstrating modest growth and maintaining a robust EBITDA margin.

Financial Highlights

The company reported a 2.1% year-on-year increase in revenue from operations, reaching Rs. 168.90 crores compared to Rs. 165.40 crores in the same quarter of the previous year. Notably, RPG Life Sciences achieved an impressive 18.1% quarter-on-quarter growth.

Despite the revenue growth, the company's profitability remained relatively stable:

• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin stood at a healthy 24.1%.
• Profit Before Tax (PBT) was Rs. 35.40 crores, slightly lower than the Rs. 36.00 crores reported in the previous year.
• Profit After Tax (PAT) came in at Rs. 26.30 crores, compared to Rs. 26.80 crores in Q1 FY25.

Segment Performance

The company's performance across its business segments showed mixed results:

Management Commentary

Mr. Ashok Nair, Managing Director of RPG Life Sciences Ltd., commented on the results: "In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach."

Nair added, "We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach."

Strategic Initiatives and Future Outlook

The company highlighted several strategic initiatives and future plans:

1. Inorganic Growth: RPG Life Sciences is actively exploring inorganic growth opportunities across both formulations and APIs to accelerate its growth trajectory.
2. Manufacturing Capacity: The company has infused Rs. 140 crores in capex since FY22 to build modern plants with approvals from regulatory bodies such as EU, TGA, and PMDA.
3. Portfolio Expansion: There's a focus on growing the immunosuppressant portfolio to over Rs. 200 crores and developing the Naprosyn brand to exceed Rs. 100 crores.
4. Digital Initiatives: Multiple digital initiatives are underway to streamline front-end and backend operations, improving efficiency and compliance while reducing costs.

Corporate Governance

The Board of Directors, in their meeting on July 25, 2025, approved the unaudited financial results and revised the policy for determination of materiality of events in accordance with amended SEBI listing regulations. The company remains committed to maintaining high standards of corporate governance and transparency.

New Appointment

In a separate announcement, RPG Life Sciences appointed Mr. Deepak Shukla as Chief Executive - API Business, effective July 28, 2025. Shukla brings approximately 25 years of experience from reputed companies in the pharmaceutical and chemical industries.

As RPG Life Sciences continues to navigate the dynamic pharmaceutical landscape, its focus on strategic execution, operational excellence, and expansion into new markets positions the company for potential growth in the coming quarters.